OM-301 / Oncolyze - LARVOL DELTA

Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Multiple Myeloma (Newswire) - "Oncolyze, which already holds an Orphan Drug Designation for its lead drug candidate OM-301 in treating acute myeloid leukemia (AML), is pleased to announce that the FDA has just granted OM-301 its second Orphan Drug Designation, for multiple myeloma."

Orphan drug • Hematological Malignancies • Multiple Myeloma • Oncology